DOI: https://doi.org/10.36347/sjmcr.2026.v14i04.056

Pages: 823-825

Cataract in young adults is uncommon and should prompt investigation for secondary causes, including drug-induced etiologies. Olanzapine, an atypical antipsychotic widely used in the management of bipolar disorder and schizophrenia, is known for its metabolic side effects, while ocular complications remain rarely reported. We describe the case of a 31-year-old male patient treated with olanzapine for several years who developed a unilateral total white cataract without any identifiable risk factors such as trauma, inflammation, or metabolic disease. Ophthalmological examination confirmed a dense cataract in the left eye and an early cortical opacity in the fellow eye. B-scan ultrasonography ruled out posterior segment abnormalities. The patient underwent successful phacoemulsification with intraocular lens implantation, achieving excellent visual recovery. The absence of alternative etiologies and the prolonged exposure to olanzapine suggest a possible association. This case highlights the need for awareness of potential ocular adverse effects of atypical antipsychotics and suggests that periodic ophthalmologic monitoring may be beneficial in patients receiving long-term therapy.